As an accessible, cell-surface ‘common receptor coordinator’, DEspR-inhibition defines a novel targeted-therapy paradigm for pancreatic cancer and glioblastoma. This evidence concerns the gene FBXW7-AS1 and familial pancreatic carcinoma.